Vernalis buys US rights to tonsillitis/ pharyngitis drug Moxatag

2 October 2015

UK-based Vernalis (LSE: VER) on Friday said it has acquired the US rights to Moxatag (amoxicillin) from US firm Pragma Pharmaceuticals for an undisclosed up-front cash payment.

The company will also pay Pragma Pharmaceuticals a further sum following the manufacture of re-launch finished dose product. The product re-launch is expected by the end of 2015.

Ian Garland, chief executive of Vernalis, said: "The acquisition of Moxatag is another important step in our transition to a commercial specialty pharmaceutical company. We are delighted that we have been able to quickly expand our primary care product portfolio and leverage our newly established US commercial infrastructure following the recent US launch of Tuzistra XR, our extended-release cough cold oral suspension. Moxatag has a strong fit with our target physician audience for Tuzistra XR and we look forward to re-launching the product in early 2016 and to its contribution to our commercial business”.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK